Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.


ICLI F., ALTUNDAG K., COSKUN U., PAYDAS S., BASARAN G., SAIP P., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011 (SCI İndekslerine Giren Dergi) identifier